Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Quantifying treatment effects using the personalized chance of longer survival.

Zhao YQ, Redman MW, LeBlanc ML.

Stat Med. 2019 Dec 10;38(28):5317-5331. doi: 10.1002/sim.8363. Epub 2019 Sep 9.

PMID:
31502297
2.

Recommended technology to relieve oral mucositis not yet available for children or young people in England or Wales.

Redman M, Harris K, Morgan JE, Phillips R.

Arch Dis Child. 2019 Dec;104(12):1238. doi: 10.1136/archdischild-2019-317542. Epub 2019 Aug 29. No abstract available.

3.

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K.

J Clin Oncol. 2019 Oct 1;37(28):2537-2547. doi: 10.1200/JCO.19.00269. Epub 2019 Aug 6.

PMID:
31386610
4.

Challenges and approaches to implementing master/basket trials in oncology.

Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR.

Blood Adv. 2019 Jul 23;3(14):2237-2243. doi: 10.1182/bloodadvances.2019031229.

5.

SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).

Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS.

J Thorac Oncol. 2019 Oct;14(10):1853-1859. doi: 10.1016/j.jtho.2019.06.027. Epub 2019 Jul 11.

PMID:
31302234
6.

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).

Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, Newman AJ 3rd, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR.

J Thorac Oncol. 2019 Oct;14(10):1847-1852. doi: 10.1016/j.jtho.2019.05.041. Epub 2019 Jun 11.

PMID:
31195180
7.

SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).

Langer CJ, Redman MW, Wade JL 3rd, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA.

J Thorac Oncol. 2019 Oct;14(10):1839-1846. doi: 10.1016/j.jtho.2019.05.029. Epub 2019 May 31.

PMID:
31158500
8.

WORKFORCE: Newly graduated doctors' experiences of conducting medical ward rounds alone: A regional cross-sectional study.

Pearce J, Govan S, Harlinska A, Tremain R, Gajebasia S, Redman M.

Future Healthc J. 2019 Feb;6(1):47-51. doi: 10.7861/futurehosp.6-1-47.

9.

How can training in care of the dying be improved?

Gajebasia S, Pearce J, Redman M, Johnson M, Finn G.

Clin Teach. 2019 Dec;16(6):610-614. doi: 10.1111/tct.12999. Epub 2019 Feb 12.

PMID:
30746854
10.

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.

Symonds L, Linden H, Gadi V, Korde L, Rodler E, Gralow J, Redman M, Baker K, Wu QV, Jenkins I, Kurland B, Garrison M, Smith J, Anderson J, Van Haelst C; Seattle Cancer Care Alliance Network Investigators, Specht J.

Clin Breast Cancer. 2019 Apr;19(2):e283-e296. doi: 10.1016/j.clbc.2018.12.008. Epub 2018 Dec 14.

PMID:
30737173
11.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

12.

Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma: Impact of Immunosuppression Type on Cancer-specific and Overall Survival.

Cook M, Baker K, Redman M, Lachance K, Nguyen MH, Parvathaneni U, Bhatia S, Nghiem P, Tseng YD.

Am J Clin Oncol. 2019 Jan;42(1):82-88. doi: 10.1097/COC.0000000000000482.

PMID:
30211723
13.

Effect of Patient Immune Status on the Efficacy of Radiation Therapy and Recurrence-Free Survival Among 805 Patients With Merkel Cell Carcinoma.

Tseng YD, Nguyen MH, Baker K, Cook M, Redman M, Lachance K, Bhatia S, Liao JJ, Apisarnthanarax S, Nghiem PT, Parvathaneni U.

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):330-339. doi: 10.1016/j.ijrobp.2018.05.075. Epub 2018 Jun 5.

PMID:
30191867
14.

Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer.

Rengan R, Redman M, Zeng J.

J Clin Oncol. 2018 Jul 1;36(19):2003-2004. doi: 10.1200/JCO.2018.78.3803. Epub 2018 May 10. No abstract available.

PMID:
29746228
15.

First-trimester metabolomic prediction of stillbirth.

Bahado-Singh RO, Syngelaki A, Mandal R, Han B, Li L, Bjorndahl TC, Wang N, Maulik D, Dong E, Turkoglu O, Tseng CL, Zeb A, Redman M, Wishart DS, Nicolaides KH.

J Matern Fetal Neonatal Med. 2019 Oct;32(20):3435-3441. doi: 10.1080/14767058.2018.1465552. Epub 2018 Apr 30.

PMID:
29712497
16.

Response to H. Nabi et al.

Cheng TD, Darke AK, Redman MW, Kelly K, Santella RM, Albain KS, Ambrosone CB.

J Natl Cancer Inst. 2018 Dec 1;110(12):1424-1425. doi: 10.1093/jnci/djy069. No abstract available.

17.

Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial.

Guerriero MK, Redman MW, Baker KK, Martins RG, Eaton K, Chow LQ, Santana-Davila R, Baik C, Goulart BH, Lee S, Rodriguez CP.

Cancer. 2018 Jul 1;124(13):2841-2849. doi: 10.1002/cncr.31407. Epub 2018 Apr 18.

18.

Ward rounds: can an aide-memoire help new doctors?

Pearce J, Redman M, Gajebasia S, Dirksen R.

Clin Teach. 2019 Apr;16(2):147-151. doi: 10.1111/tct.12789. Epub 2018 Apr 17.

PMID:
29664168
19.

Knotty issues in postpyloric feeding.

Redman M, Campbell D.

Arch Dis Child. 2019 Feb;104(2):188. doi: 10.1136/archdischild-2017-314626. Epub 2018 Jan 30. No abstract available.

PMID:
29382636
20.

Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).

Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly K, Santella RM, Albain KS, Ambrosone CB.

J Natl Cancer Inst. 2018 Jul 1;110(7):734-742. doi: 10.1093/jnci/djx260.

21.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR.

Lancet Oncol. 2018 Jan;19(1):101-114. doi: 10.1016/S1470-2045(17)30694-0. Epub 2017 Nov 20.

22.

Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer.

Yuan Z, Baker K, Redman MW, Wang L, Adams SV, Yu M, Dickinson B, Makar K, Ulrich N, Böhm J, Wurscher M, Westerhoff M, Medwell S, Moonka R, Sinanan M, Fichera A, Vickers K, Grady WM.

Br J Cancer. 2017 Oct 10;117(8):1202-1210. doi: 10.1038/bjc.2017.266. Epub 2017 Aug 15.

23.

Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials.

West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara DR.

Clin Lung Cancer. 2018 Jan;19(1):84-92. doi: 10.1016/j.cllc.2017.06.016. Epub 2017 Jul 6.

24.

Care of the dying: a qualitative exploration of Foundation Year doctors' experiences.

Redman M, Pearce J, Gajebasia S, Johnson M, Finn G.

Med Educ. 2017 Oct;51(10):1025-1036. doi: 10.1111/medu.13358. Epub 2017 Jul 26.

PMID:
28744956
25.

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K.

J Thorac Oncol. 2017 Aug;12(8):1299-1308. doi: 10.1016/j.jtho.2017.05.021. Epub 2017 Jun 6.

26.

The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.

Cohen SA, Yu M, Baker K, Redman M, Wu C, Heinzerling TJ, Wirtz RM, Charalambous E, Pentheroudakis G, Kotoula V, Kalogeras KT, Fountzilas G, Grady WM.

Clin Epigenetics. 2017 May 2;9:46. doi: 10.1186/s13148-017-0347-1. eCollection 2017.

27.

T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.

Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL.

Cancer. 2017 Sep 1;123(17):3291-3304. doi: 10.1002/cncr.30726. Epub 2017 May 2.

28.

Using a multifaceted quality improvement initiative to reverse the rising trend of cesarean births.

Ogunyemi D, McGlynn S, Ronk A, Knudsen P, Andrews-Johnson T, Raczkiewicz A, Jovanovski A, Kaur S, Dykowski M, Redman M, Bahado-Singh R.

J Matern Fetal Neonatal Med. 2018 Mar;31(5):567-579. doi: 10.1080/14767058.2017.1292244. Epub 2017 Feb 28.

PMID:
28282770
29.

Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study.

Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, Morishima C, Hutchinson K, Mudgistratova L, Blom A, Iyer J, Moshiri AS, Tarabadkar ES, Carter JJ, Bhatia S, Kawasumi M, Galloway DA, Wener MH, Nghiem P.

Cancer. 2017 Apr 15;123(8):1464-1474. doi: 10.1002/cncr.30475. Epub 2016 Dec 7.

30.

Academic poster design at a national conference: a need for standardised guidance?

Gopal A, Redman M, Cox D, Foreman D, Elsey E, Fleming S.

Clin Teach. 2017 Oct;14(5):360-364. doi: 10.1111/tct.12584. Epub 2016 Dec 7.

PMID:
27925391
31.

Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.

Pellini Ferreira B, Redman M, Baker KK, Martins R, Eaton KD, Chow LQM, Baik CS, Goulart B, Lee SM, Santana-Davila R, Rodriguez CP.

Laryngoscope. 2017 Jul;127(7):1583-1588. doi: 10.1002/lary.26422. Epub 2016 Dec 1.

PMID:
27905113
32.

Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.

Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, Adjei AA, Gandara D, Ramalingam SS, Vokes EE.

J Clin Oncol. 2016 Nov 20;34(33):3992-3999. doi: 10.1200/JCO.2016.67.7088. Epub 2016 Sep 30.

33.

Reliability of measurements performed on two dimensional and three dimensional computed tomography in glenoid assessment for instability.

Kubicka AM, Stefaniak J, Lubiatowski P, Długosz J, Dzianach M, Redman M, Piontek J, Romanowski L.

Int Orthop. 2016 Dec;40(12):2581-2588. Epub 2016 Aug 5.

PMID:
27492723
34.

Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.

Araki D, Redman MW, Martins R, Eaton K, Baik C, Chow L, Goulart B, Lee S, Santana-Davila R, Liao J, Parvathaneni U, Laramore G, Futran N, Mendez E, Bhrany A, Rodriguez CP.

Head Neck. 2016 Sep;38(9):1318-23. doi: 10.1002/hed.24437. Epub 2016 Apr 7.

PMID:
27061333
35.

What is CRISPR/Cas9?

Redman M, King A, Watson C, King D.

Arch Dis Child Educ Pract Ed. 2016 Aug;101(4):213-5. doi: 10.1136/archdischild-2016-310459. Epub 2016 Apr 8. Review. No abstract available.

36.

Scientific Advances in Lung Cancer 2015.

Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI.

J Thorac Oncol. 2016 May;11(5):613-638. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22. Review.

37.

Are K-12 school environments harming students with obesity? A qualitative study of classroom teachers.

Kenney EL, Redman MT, Criss S, Sonneville KR, Austin SB.

Eat Weight Disord. 2017 Mar;22(1):141-152. doi: 10.1007/s40519-016-0268-6. Epub 2016 Mar 15.

PMID:
26980318
38.

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.

Lara PN Jr, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL 3rd, Hirsch FR, Mack PC, Gandara DR.

J Thorac Oncol. 2016 Mar;11(3):420-5. doi: 10.1016/j.jtho.2015.11.003. Epub 2015 Dec 25.

39.

Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials.

Gandara DR, Redman M, Hirsch FR.

JAMA Oncol. 2016 Mar;2(3):300-1. doi: 10.1001/jamaoncol.2015.4920. No abstract available.

PMID:
26720042
40.

Model selection and inference for censored lifetime medical expenditures.

Johnson BA, Long Q, Huang Y, Chansky K, Redman M.

Biometrics. 2016 Sep;72(3):731-41. doi: 10.1111/biom.12464. Epub 2015 Dec 21.

41.

Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.

Lara PN Jr, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR.

Clin Lung Cancer. 2016 Mar;17(2):113-8.e1-2. doi: 10.1016/j.cllc.2015.09.003. Epub 2015 Oct 23.

42.

The Master Protocol Concept.

Redman MW, Allegra CJ.

Semin Oncol. 2015 Oct;42(5):724-30. doi: 10.1053/j.seminoncol.2015.07.009. Epub 2015 Jul 10. Review.

43.

Lung-MAP--framework, overview, and design principles.

Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA.

Chin Clin Oncol. 2015 Sep;4(3):36. doi: 10.3978/j.issn.2304-3865.2015.09.02. Review.

44.

Cognitive Behavioral Stress Management for Healthy Women at Risk for Breast Cancer: a Novel Application of a Proven Intervention.

McGregor BA, Dolan ED, Murphy KM, Sannes TS, Highland KB, Albano DL, Ward AA, Charbonneau AM, Redman MW, Ceballos RM.

Ann Behav Med. 2015 Dec;49(6):873-84. doi: 10.1007/s12160-015-9726-z.

45.

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.

Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ.

J Thorac Oncol. 2015 Jul;10(7):1099-106. doi: 10.1097/JTO.0000000000000548.

46.

Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer".

Lara PN Jr, Gandara DR, Redman MW.

J Thorac Oncol. 2015 May;10(5):e36. doi: 10.1097/JTO.0000000000000515. No abstract available.

47.

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.

Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA.

Clin Cancer Res. 2015 Apr 1;21(7):1514-24. doi: 10.1158/1078-0432.CCR-13-3473. Epub 2015 Feb 13.

48.

Innovative Clinical Trials: The LUNG-MAP Study.

Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR.

Clin Pharmacol Ther. 2015 May;97(5):488-91. doi: 10.1002/cpt.88. Review.

PMID:
25676724
49.

FDG PET-CT in follicular lymphoma: a case-based evidence review.

Smith SD, Redman M, Dunleavy K.

Blood. 2015 Feb 12;125(7):1078-82. doi: 10.1182/blood-2014-11-537522. Epub 2014 Dec 19. Review. No abstract available.

50.

Balancing "we" and "me".

Congdon C, Flynn D, Redman M.

Harv Bus Rev. 2014 Oct;92(10):50-7, 121.

PMID:
25509575

Supplemental Content

Loading ...
Support Center